接受分子靶向药物和免疫检查点抑制剂患者的药物相关性肺炎的胸部CT诊断与临床管理:Fleischner学会立场文件
该立场文件针对接受分子靶向药物和免疫检查点抑制剂(ICIs)的癌症患者,指出肺毒性频率增加且谱系扩大。DRP诊断通常通过排除其他已知原因实现。症状可从轻微或无到危及生命甚至快速进展至死亡。影像特征应按肺实质异常分布以影像模式方法评估,CT模式反映急性(弥漫性肺泡损伤)、短暂性(单纯性肺嗜酸粒细胞增多症)、亚急性间质性病(机化性肺炎和过敏性肺炎)及慢性间质性病(非特异性间质性肺炎)。治疗一般包括停药、免疫抑制治疗或两者联合,并支持措施最终包括补氧和重症监护。
要点
- DRP诊断通常通过排除其他潜在已知原因实现,需结合用药史与影像。
- 影像评估应采用影像模式方法,结合肺实质异常分布;CT模式包括弥漫性肺泡损伤、单纯性肺嗜酸粒细胞增多症、机化性肺炎、过敏性肺炎和非特异性间质性肺炎。
- 单一药物可关联多种影像模式,认识DRP发生率和危险因素日益重要。
- 症状严重程度可从轻微或无到危及生命并快速进展至死亡。
- 治疗一般包括停药、免疫抑制治疗或两者联合,并支持措施最终包括补氧和重症监护。
适用人群与场景
- 接受分子靶向药物和免疫检查点抑制剂(ICIs)的患者,尤其是癌症患者。
诊断标准与关键阈值
- DRP诊断通常通过排除其他潜在已知原因实现。
- 影像特征应按肺实质异常分布以影像模式方法评估。
处置流程与药物剂量
- 对疑似DRP患者,治疗一般包括停药、免疫抑制治疗或两者联合。
- 支持措施最终包括补氧和重症监护。
红旗征与不能漏的情况
- 症状严重程度可从轻微或无到危及生命并快速进展至死亡。
证据类型、等级与局限
- 证据类型:Fleischner学会立场文件(专家共识)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对接受分子靶向药物或ICIs的癌症患者,出现肺部异常时应按影像模式方法评估CT,以辅助DRP诊断。
- 疑似DRP时,治疗一般包括停药、免疫抑制治疗或两者联合,并给予支持措施,最终包括补氧和重症监护。
指南或共识出处
- Fleischner学会立场文件:Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society.
提炼说明
- 本条依据论文摘要整理;摘要未涉及「研究设计与关键结果」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Use of molecular targeting agents and immune checkpoint inhibitors (ICIs) has increased the frequency and broadened the spectrum of lung toxicity, particularly in patients with cancer. The diagnosis of drug-related pneumonitis (DRP) is usually achieved by excluding other potential known causes. Awareness of the incidence and risk factors for DRP is becoming increasingly important. The severity of symptoms associated with DRP may range from mild or none to life-threatening with rapid progression to death. Imaging features of DRP should be assessed in consideration of the distribution of lung parenchymal abnormalities (radiologic pattern approach). The CT patterns reflect acute (diffuse alveolar damage) interstitial pneumonia and transient (simple pulmonary eosinophilia) lung abnormality, subacute interstitial disease (organizing pneumonia and hypersensitivity pneumonitis), and chronic interstitial disease (nonspecific interstitial pneumonia). A single drug can be associated with multiple radiologic patterns. Treatment of a patient suspected of having DRP generally consists of drug discontinuation, immunosuppressive therapy, or both, along with supportive measures eventually including supplemental oxygen and intensive care. In this position paper, the authors provide diagnostic criteria and management recommendations for DRP that should be of interest to radiologists, clinicians, clinical trialists, and trial sponsors, among others.
参考来源
- Johkoh T, Lee KS, Nishino M, et al. Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society. Chest. 2021. PMID: 33450293. doi:10.1016/j.chest.2020.11.027
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。